| Anton M Melnyk Jr, MD,FACP | |
|
1100 N 19th St, Suite 1a, Abilene, TX 79601-2344 | |
| (325) 672-4368 | |
| (325) 672-3108 |
| Full Name | Anton M Melnyk Jr |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 36 Years |
| Location | 1100 N 19th St, Abilene, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801834544 | NPI | - | NPPES |
| 046352301 | Medicaid | TX | |
| 8R1503 | Other | TX | BLUE CROSS OF TX |
| 117946701 | Medicaid | TX | |
| 117946702 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | J8058 (Texas) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | J8058 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hendrick Medical Center | Abilene, TX | Hospital |
| Eastland Memorial Hospital | Eastland, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Oncology Pa | 5395658934 | 855 |
News Archive
Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.
Women with high levels of a common liver enzyme measured prior to pregnancy were twice as likely to subsequently develop gestational diabetes than those with the lowest levels, according to a Kaiser Permanente study published today in the journal Diabetes Care.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
New research from Sanford Burnham Prebys Medical Discovery Institute (SBP) at Lake Nona uncovers the modus operandi of a mysterious molecule called SPRIGHTLY that has been previously implicated in colorectal cancer, breast cancer, and melanoma.
› Verified 9 days ago
| Entity Name | Texas Oncology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811944101 PECOS PAC ID: 5395658934 Enrollment ID: O20031124000323 |
News Archive
Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.
Women with high levels of a common liver enzyme measured prior to pregnancy were twice as likely to subsequently develop gestational diabetes than those with the lowest levels, according to a Kaiser Permanente study published today in the journal Diabetes Care.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
New research from Sanford Burnham Prebys Medical Discovery Institute (SBP) at Lake Nona uncovers the modus operandi of a mysterious molecule called SPRIGHTLY that has been previously implicated in colorectal cancer, breast cancer, and melanoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anton M Melnyk Jr, MD,FACP Po Box 911230, Dallas, TX 75391-1230 Ph: (972) 997-8000 | Anton M Melnyk Jr, MD,FACP 1100 N 19th St, Suite 1a, Abilene, TX 79601-2344 Ph: (325) 672-4368 |
News Archive
Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.
Women with high levels of a common liver enzyme measured prior to pregnancy were twice as likely to subsequently develop gestational diabetes than those with the lowest levels, according to a Kaiser Permanente study published today in the journal Diabetes Care.
Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.
New research from Sanford Burnham Prebys Medical Discovery Institute (SBP) at Lake Nona uncovers the modus operandi of a mysterious molecule called SPRIGHTLY that has been previously implicated in colorectal cancer, breast cancer, and melanoma.
› Verified 9 days ago
Lindsey Pittillo, FNP-BC Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1957 Antilley Rd, Abilene, TX 79606 Phone: 325-692-0188 | |
Dr. Ralphie Alberto Rosario Feliciano, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1665 Antilley Rd Ste 260, Abilene, TX 79606 Phone: 325-793-5223 Fax: 325-793-5236 | |
Dr. Amelia Lorenzo, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4225 Woods Pl, Abilene, TX 79602 Phone: 325-695-3252 Fax: 325-695-3414 | |
Mustapha Ali Khalife, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2000 Pine St, Abilene, TX 79601 Phone: 253-670-6340 Fax: 903-877-7825 | |
Dr. Ralph F. Heaven, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1100 N 19th St, Suite 1a, Abilene, TX 79601 Phone: 325-672-4368 Fax: 325-672-3108 | |
Mrs. Amelia Y Yeh, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3210 Antilley Rd, Abilene, TX 79606 Phone: 325-795-1600 Fax: 325-692-4780 | |
Dr. Farley Berry Graden Neasman Iii, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6200 Regional Plz Ste 1675, Abilene, TX 79606 Phone: 325-428-4790 Fax: 325-428-5855 |